ProPhase Labs (PRPH) announced the successful completion of a key validation study evaluating the performance of the BE-Smart molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart achieved greater than a 95% technical success rate, confirming the BE-Smart’s ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett’s esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart with expected clinical launch in the next 2-3 quarters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs announces formation of Clinical Science Advisory Board
- ProPhase Labs’ Earnings Call: Strategic Moves Amid Challenges
- ProPhase Labs Reports Q1 2025 Earnings and Strategic Developments
- ProPhase Labs says CEO voluntarily agrees to defer salary by over two thirds
- ProPhase Labs expects to receive 6-month extension for Nasdaq listing